The CJC-1295 / Ipamorelin blend contains two synthetic peptides with complementary mechanisms of action. CJC-1295 is an analog of growth hormone–releasing hormone (GHRH), while Ipamorelin is a selective ghrelin receptor agonist. In laboratory research, this combination has been examined for its coordinated influence on growth hormone secretion pathways in non-human models. This compound is intended for in vitro or animal research only and is not for human or veterinary use.
Peptides will arrive in a lyophilized (powder) form for maximum stability
$95.00
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro laboratory research only. In-vitro studies (Latin: “in glass”) are performed outside of living organisms. These products are not medicines or drugs, and they have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Under no circumstances should these products be introduced into the human or animal body, whether by injection, ingestion, topical application, or any other route. Bodily introduction is strictly prohibited by law.
Gold Standard Peptides is committed to providing high-quality research chemicals to the American market.
Mon – Fri / Except Holidays
Orders placed and paid after 12 PM EST
are shipped the following business day
30 N Gould St Ste R, Sheridan,
WY 82801 USA
All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Gold Standard Peptides is a chemical supplier. Gold Standard Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Gold Standard Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.